- Myo-inositol is one of the best-evidenced ingredients in the current supplement-hype cycle: a systematic review and meta-analysis that directly informed the 2023 International PCOS Guideline found it improves metabolic and some hormonal markers, but graded the evidence for hard reproductive outcomes as low-certainty (Fitz 2024, J Clin Endocrinol Metab).
- The official 2023 guideline itself says inositol "could be considered" for metabolic measures but that specific types, doses, or combinations "cannot currently be recommended", and inositol for infertility should be treated as experimental therapy (❤◯◯◯ low certainty) (Teede 2023, J Clin Endocrinol Metab).
- Metabolic effects (insulin resistance/HOMA-IR, fasting insulin) are more consistently supported than reproductive endpoints like live birth (PMC6617769; DiNicolantonio & O'Keefe 2022, Open Heart).
- The widely marketed 40:1 myo-inositol : D-chiro-inositol ratio is covered by pharmaceutical patents held by Lo.Li. Pharma S.r.l. (inventor Vittorio Unfer), whose affiliated researchers authored many of the studies establishing "40:1 is optimal" — a financial conflict readers should know about (EP2782559B1, Lo.Li. Pharma; PMC7140126).
- Well tolerated at studied doses (2–4 g/day long-term, up to 18 g/day short-term); main risks are mild GI upset and additive glucose-lowering with diabetes medications (Open Heart).
- Overall evidence grade: Moderate for PCOS metabolic markers; guideline-endorsed but Weak/low-certainty for live birth and other reproductive endpoints.
Table of contents
- Evidence summary
- What myo-inositol is
- All forms and grades
- How it works
- The hype vs the evidence
- Benefits by claim
- What works and what does not
- Risks and all side effects
- All interactions
- Who should avoid myo-inositol
- Dosage and how to take
- Animal and in-vitro evidence excluded
- Independent funding and conflict notes
- Frequently asked questions
- Sources and funding notes
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Myo-inositol improves insulin resistance/HOMA-IR in PCOS | Multiple RCTs and meta-analyses show reduced HOMA-IR, fasting insulin/glucose over ~8–24 weeks | PMC6617769; Unfer 2017, Endocrine Connections | Mixed academic; some authors linked to inositol-patent holder (see funding notes) | Moderate |
| Myo-inositol improves ovulation/menstrual regularity | Guideline-informing systematic review finds benefit for some hormonal/cycle markers, but overall efficacy "indeterminate" | Fitz 2024, J Clin Endocrinol Metab | Publicly-funded academic consortium (Monash, Harvard/MGH, Western Sydney) — independent | Moderate |
| Inositol (any form) as fertility/live-birth therapy for PCOS | 2023 International PCOS Guideline: "experimental therapy," benefits/risks "too uncertain to recommend" (certainty rating ❤◯◯◯, lowest tier) | Teede 2023, J Clin Endocrinol Metab | International guideline panel — independent | Weak (guideline-endorsed but low-certainty) |
| Myo-inositol reduces androgens (testosterone, LH:FSH) | Meta-analyses show reductions in some studies; one meta-analysis found no significant change in total testosterone | Unfer 2017; Pundir 2022 meta-analysis | Mixed; Pundir 2022 independent, found largely null results | Contested |
| Myo-inositol (4g/day) may reduce gestational diabetes incidence | Meta-analysis of 6 RCTs: RR 0.54 (95% CI 0.30–0.96, n=887); certainty low-to-very-low | GDM meta-analysis, PMC10692440 | Academic; low/very-low GRADE certainty | Weak |
| 40:1 myo-inositol:D-chiro-inositol ratio is the "optimal" formulation | Ratio derived from plasma physiology; supporting trials frequently authored by researchers tied to the ratio's patent holder | Nordio 2019; EP2782559B1 | Conflicted — patent holder (Lo.Li. Pharma) and inventor (Vittorio Unfer) are co-authors on key supporting studies | Contested |
| Myo-inositol is well tolerated at 2–4 g/day long-term or 18 g/day short-term | Tolerability data across trials; mild GI effects at higher doses | DiNicolantonio & O'Keefe 2022, Open Heart | Independent (cardiology editorial synthesizing trial data) | Moderate |
What myo-inositol is
Myo-inositol is a naturally occurring sugar alcohol, once informally labeled "vitamin B8" even though it is not a true vitamin because the body synthesizes it endogenously — the kidneys alone make roughly 2 grams per day — and it is also obtained from fruits, grains, beans, and nuts (DiNicolantonio & O'Keefe 2022, Open Heart). It is one of nine stereoisomers of inositol, of which myo-inositol (MYO) and D-chiro-inositol (DCI) are the two studied for metabolic and reproductive effects; both are believed to act downstream of the insulin receptor as second messengers (Clinical Medicine Insights: Case Reports, PMC10981332). Myo-inositol has moved from a niche fertility-clinic supplement into a mainstream women's-health and biohacking product, marketed heavily for polycystic ovary syndrome (PCOS), ovulation and fertility support, insulin resistance, and vague "hormone balance" claims (NutraIngredients/Spate).
All forms and grades
Myo-inositol supplements are sold in several forms that differ mainly in whether D-chiro-inositol is added and in what ratio.
| Form | Composition | Typical dose | Notes |
|---|---|---|---|
| Myo-inositol powder (single ingredient) | Pure myo-inositol, usually dissolved in water | 2–4 g/day, often split into two doses | Most-studied form in PCOS metabolic-marker trials (Open Heart) |
| Myo-inositol capsules/tablets | Pure myo-inositol in fixed-dose capsule | 2–4 g/day | Same active ingredient as powder; convenience format |
| Myo-inositol + D-chiro-inositol blend (40:1) | Myo-inositol and D-chiro-inositol combined at a weight ratio at or near 40:1 | Commonly ~2 g myo-inositol + ~50 mg D-chiro-inositol per dose, totaling ~4 g myo-inositol equivalent/day | Ratio reflects normal human blood plasma MYO:DCI ratio; the subject of active pharmaceutical patents (EP2782559B1) |
| Myo-inositol + D-chiro-inositol blend (lower ratios, e.g., 3.6:1) | Higher relative DCI content | Varies by product | Preliminary evidence from a single multicenter Spanish trial suggested a lower ratio may improve pregnancy/live-birth rates versus 40:1, but this remains an early, single-source finding (PMC10981332) |
| Myo-inositol + folic acid | Myo-inositol combined with folic acid (200–400 mcg) | 2 g myo-inositol + folic acid | Common PCOS/fertility-clinic combination product |
How it works
Myo-inositol and D-chiro-inositol function as insulin-signaling second messengers: after insulin binds its receptor, inositolphosphoglycans derived from these molecules help relay the signal that mediates glucose uptake and use inside cells (PMC10981332; PMC8371888, network meta-analysis). In tissues such as the ovary, myo-inositol is thought to help restore FSH sensitivity and improve oocyte quality, while D-chiro-inositol is more associated with improving insulin sensitivity in liver and muscle, which secondarily lowers circulating insulin and androgen production (PMC7140126). This dual mechanism is the physiological rationale offered for combining the two isomers rather than using myo-inositol alone. Because insulin resistance and compensatory hyperinsulinemia are central drivers of PCOS's hormonal disruption in a large share of patients, an insulin-sensitizing supplement is mechanistically plausible as an adjunct to lower androgen levels and support ovulation (Open Heart). This mechanism is grounded in human physiology and pharmacology reviews rather than animal or in-vitro data, but it remains a proposed pathway explaining trial results rather than a directly observed real-time mechanism in patients.
The hype vs the evidence
Online and clinic marketing for myo-inositol clusters around four claims: it "fixes" PCOS, it boosts ovulation and fertility, it reverses insulin resistance, and it restores general "hormone balance." The human evidence supports a narrower and more qualified picture:
- PCOS metabolic markers: A systematic review and meta-analysis conducted specifically to inform the 2023 International PCOS Guideline found inositol improves some metabolic and hormonal markers — but concluded overall efficacy for PCOS management is "limited and inconclusive," and that clinicians and patients should weigh this uncertainty in shared decision-making (Fitz 2024, J Clin Endocrinol Metab).
- Ovulation/fertility: The guideline itself designates inositol for infertility as "experimental therapy" with benefits and risks "currently too uncertain to recommend," rated at the guideline's lowest certainty tier (❤◯◯◯) (Teede 2023, J Clin Endocrinol Metab). This directly contradicts the common marketing framing of myo-inositol as a proven fertility booster.
- Insulin resistance: This is the area with the most consistent positive human-trial signal, with several RCTs and meta-analyses reporting reduced HOMA-IR and fasting insulin/glucose (PMC6617769). However, a 2022 meta-analysis focused on anthropometric, metabolic, and endocrine outcomes found no significant improvement in fasting insulin, fasting glucose, HOMA-IR, or several hormone levels after myo-inositol treatment, with high heterogeneity between studies flagged as a limiting factor (Pundir 2022, meta-analysis) — a genuinely mixed picture rather than a uniform positive.
- "Hormone balance": This marketing phrase has no fixed clinical definition. The actual measured hormonal effects (LH, LH:FSH ratio, androgens) vary across trials, with some meta-analyses reporting improvement (Unfer 2017) and others finding no significant change in total testosterone (Pundir 2022).
The bottom line: myo-inositol has genuinely stronger, guideline-referenced evidence than most trending supplements on the market today, but marketing routinely overstates certainty on reproductive outcomes specifically, where the guideline itself uses the word "experimental."
Benefits by claim
Insulin resistance and metabolic markers
Reviews of RCTs report that myo-inositol, typically at 4 g/day, improves HOMA-IR, fasting glucose/insulin, and adiponectin over roughly 8 weeks in insulin-resistant women (PMC6617769). An earlier meta-analysis of 9 studies found significant reductions in fasting serum insulin and the HOMA index after myo-inositol supplementation in PCOS patients, describing effect sizes as potentially clinically relevant (Unfer 2017, Endocrine Connections). Countering this, the independent 2022 meta-analysis by Pundir and colleagues found no significant improvement in fasting insulin, fasting glucose, or HOMA in a separately pooled set of RCTs, attributing the discrepancy partly to high between-study heterogeneity (Pundir 2022). Net read: the metabolic-marker signal is real and guideline-referenced but not as uniformly positive as the most-cited meta-analyses suggest once conflicting reviews are weighed together.
Ovulation and menstrual regularity
A network meta-analysis found myo-inositol combined with D-chiro-inositol was associated with a substantially greater improvement in menstrual frequency than metformin alone (odds ratio 14.70; 95% CI 2.31–93.58), and produced the best overall improvement in menstrual frequency among the insulin-sensitizing options compared (PMC8371888). The 2023 PCOS Guideline's own review notes reproductive outcomes including menstrual regularity, ovulation rate, pregnancy rates, and live-birth rate were reported across up to 13 studies, but the guideline's formal recommendation still treats inositol's clinical benefit for ovulation as limited (Teede 2023). Independence: the network meta-analysis is independent academic work; the guideline panel is an international, publicly-funded consensus body — both rated independent, high credibility.
Live birth and fertility (guideline-mentioned, low-certainty)
This is the claim most exaggerated in consumer marketing. The 2023 International PCOS Guideline explicitly states: "Inositol in any form alone, or in combination with other therapies, should be considered experimental therapy in women with PCOS with infertility, with benefits and risks currently too uncertain to recommend the use of these agents as fertility therapies," rated at the guideline's lowest evidence-certainty tier (❤◯◯◯) (Teede 2023, J Clin Endocrinol Metab; Flinders University PDF of recommendations). A 2025 commentary further notes that current international and national guidelines "do not endorse [myo-inositol] as a primary treatment for infertility related to PCOS," and that data on live births specifically remain insufficient even in IVF contexts (Reproductive BioMedicine Online commentary, 2025).
Gestational diabetes prevention
A meta-analysis of 6 RCTs (n=887) found that standard-dose myo-inositol (4 g/day) may reduce the incidence of gestational diabetes mellitus (RR 0.54; 95% CI 0.30–0.96), though the authors rated the certainty of this evidence as low-to-very-low (PMC10692440). This is a promising but preliminary signal, not an established preventive indication.
Androgen levels and hyperandrogenism
Results are contested. Some meta-analyses and reviews report reductions in testosterone, free androgen index, and LH:FSH ratio with myo-inositol treatment (Unfer 2017; Laganà 2024 expert opinion), while the independent 2022 Pundir meta-analysis found no significant improvement in total testosterone, LH, FSH, estradiol, SHBG, or DHEA-S after myo-inositol treatment, with only androstenedione and prolactin showing change (Pundir 2022). The 2023 guideline separately notes metformin is preferred over inositol specifically for hirsutism (Teede 2023).
What works and what does not
| Claim | Verdict | Evidence basis |
|---|---|---|
| Improves insulin resistance/HOMA-IR in PCOS | Supported by several trials, but one independent meta-analysis found null results | PMC6617769 vs. Pundir 2022 |
| Improves menstrual regularity/ovulation frequency | Supported, moderate confidence, better than metformin in network meta-analysis | PMC8371888 |
| Improves live birth rates in PCOS infertility | Not established — explicitly "experimental therapy" per guideline | Teede 2023 |
| Reduces androgens/hyperandrogenism | Contested — mixed results across meta-analyses | Unfer 2017; Pundir 2022 |
| Prevents gestational diabetes | Promising signal, low-certainty evidence | PMC10692440 |
| 40:1 MYO:DCI ratio is proven superior to other ratios | Not independently confirmed — key supporting research tied to patent holder | EP2782559B1; Nordio 2019 |
| "Fixes" PCOS as a standalone treatment | Not supported — guideline frames it as an adjunct with "limited clinical benefits" | Teede 2023 |
Risks and all side effects
| Side effect | Frequency/context | Source |
|---|---|---|
| Mild GI upset (nausea, gas, diarrhea) | Reported at higher doses; generally mild and self-limited | DiNicolantonio & O'Keefe 2022, Open Heart |
| Tolerability at 18 g/day for 3 months | Well tolerated in trial conditions | Open Heart |
| Tolerability at 4 g/day for 12 months | Well tolerated in trial conditions | Open Heart |
| Fewer GI side effects than metformin | Consistently reported across comparative trials | Teede 2023; PMC10886614 |
| Hypoglycemia risk (in context of diabetes medication) | Theoretical/additive, not a standalone effect in non-diabetic users | Open Heart |
| Overall safety and side-effect profile in PCOS trials | 2023 Guideline states plainly: "Side effects and safety are not known for inositol" as a formal safety determination for fertility use | Teede 2023 |
No serious adverse events have been consistently documented in human PCOS or gestational-diabetes-prevention trials at studied doses. The main caveat is that the guideline panel itself — a stricter and more independent standard than most trial authors apply — explicitly declines to certify inositol's safety and efficacy profile as well-characterized for fertility use, which should temper confidence beyond what individual positive trials suggest.
All interactions
| Drug/substance class | Mechanism of concern | Severity/guidance | Evidence status |
|---|---|---|---|
| Antidiabetic medications (insulin, metformin, sulfonylureas) | Myo-inositol's insulin-sensitizing, glucose-lowering activity could be additive with glucose-lowering drugs | Monitor blood glucose; risk of hypoglycemia with concurrent use | Mechanism-based, extrapolated from insulin-sensitizing trial effects (Open Heart) |
| Fertility medications (clomiphene, letrozole, gonadotropins) | Often co-administered in fertility-clinic protocols; no established adverse interaction, but combined use is generally under specialist supervision | Use under fertility specialist guidance rather than self-directed stacking | Guideline and case-series context (PMC10981332) |
| Anticoagulants/antiplatelets, antidepressants (SSRIs/SNRIs), sedatives, antihypertensives, thyroid medication, statins, PPIs, oral contraceptives, antibiotics, antiepileptics, immunosuppressants | No documented mechanism identified in the reviewed literature | No specific guidance available | Data gap |
Who should avoid myo-inositol
- People on insulin, metformin, sulfonylureas, or other glucose-lowering medications should use myo-inositol only with medical monitoring, given the additive glucose-lowering mechanism (Open Heart).
- Anyone treating infertility hoping for a guaranteed live-birth benefit should know the leading international guideline rates this use as experimental with unknown risk-benefit balance, not a proven treatment (Teede 2023).
- Pregnant individuals should coordinate use with a treating clinician or fertility specialist rather than self-supplementing, even though trial doses used to study gestational diabetes prevention were generally well tolerated (PMC10692440; Open Heart).
- Anyone choosing a branded 40:1 or other ratio-specific MYO:DCI product based purely on ratio marketing should know the "optimal ratio" literature is disproportionately authored by researchers and companies with a patent interest in that ratio (EP2782559B1).
Dosage and how to take
| Parameter | Value | Source |
|---|---|---|
| Typical studied dose (myo-inositol alone) | 2–4 g/day, often split into two doses | DiNicolantonio & O'Keefe 2022, Open Heart |
| Common MYO:DCI blend ratio | 40:1 (reflects normal plasma ratio), commonly dosed to deliver ~4 g myo-inositol equivalent/day | Nordio 2019 |
| Short-term high-dose tolerability | Up to 18 g/day for 3 months well tolerated in trials | Open Heart |
| Long-term tolerability | 4 g/day for up to 12 months well tolerated in trials | Open Heart |
| Guideline position on specific dose/ratio recommendations | "Specific types, doses, or combinations of inositol cannot currently be recommended... due to a lack of quality evidence" | Teede 2023 |
| Regulatory status (US) | GRAS as a direct food additive and dietary supplement (21 CFR 184.1370 / 582.5370) | CIR report |
Animal and in-vitro evidence excluded
This review relies on independent human-trial evidence only. No animal or in-vitro studies were used to support any efficacy or safety conclusion in this article; the underlying research file consulted for myo-inositol drew exclusively from human RCTs, meta-analyses of human trials, and the human-data-based 2023 International PCOS Guideline systematic review (Fitz 2024; Teede 2023). No in-vitro (non-human) evidence was needed or used for this ingredient, since adequate human trial data exists for the mechanistic and clinical claims discussed above.
Independent funding and conflict notes
| Source | Funding/affiliation | Independence rating |
|---|---|---|
| Fitz 2024 / Teede 2023 guideline systematic review | Publicly-funded international academic consortium (Monash University, Harvard/Massachusetts General Hospital, Western Sydney University) | Independent |
| 2023 International PCOS Guideline | International multi-society guideline panel, publicly funded process | Independent |
| Pundir 2022 meta-analysis | Academic; independent | Independent |
| PMC8371888 network meta-analysis | Academic; independent | Independent |
| Unfer 2017, Endocrine Connections | Lead author Vittorio Unfer is the inventor on multiple MYO:DCI ratio patents assigned to Lo.Li. Pharma S.r.l. | Conflicted — patent-holder authorship |
| Nordio 2019, 40:1 ratio study | Research supporting the patented 40:1 ratio; overlapping authorship with Lo.Li. Pharma-affiliated researchers | Conflicted — flagged, not used alone to support ratio superiority claims |
| EP2782559B1 patent (Lo.Li. Pharma S.r.l., inventor Vittorio Unfer) | Pharmaceutical company patent covering 10:1–100:1 MYO:DCI ratios, including the commonly marketed 40:1 | Industry patent — direct financial interest disclosed |
| Clinical Medicine Insights: Case Reports, 3.6:1 ratio case series | Small case series testing an alternative, more DCI-heavy ratio; preliminary | Independence of funding not fully disclosed in source; treat as preliminary |
| DiNicolantonio & O'Keefe 2022, Open Heart | Cardiology editorial/narrative review synthesizing trial data; no industry funding disclosed | Independent (context/dosing synthesis, not a primary trial) |
| GDM meta-analysis, PMC10692440 | Academic; independent | Independent |
Frequently asked questions
Does myo-inositol actually help with PCOS?
For metabolic and some hormonal markers, yes with moderate confidence — multiple RCTs and meta-analyses show improvements in insulin resistance measures, though one independent 2022 meta-analysis found null results on several of these same markers (PMC6617769; Pundir 2022). The 2023 International PCOS Guideline concludes overall efficacy is "limited and inconclusive," and it should be considered based on individual preferences rather than as a guaranteed fix (Fitz 2024; Teede 2023).
Will myo-inositol improve my chances of getting pregnant or having a live birth?
The evidence for this specific claim is the weakest part of the myo-inositol story. The 2023 guideline explicitly labels inositol for PCOS-related infertility as "experimental therapy," with benefits and risks "too uncertain to recommend," at its lowest certainty rating (Teede 2023). A 2025 commentary similarly notes that current international and national guidelines do not endorse myo-inositol as a primary infertility treatment (Reproductive BioMedicine Online, 2025).
What's the difference between myo-inositol alone and the 40:1 blend?
Myo-inositol alone is the most-studied single ingredient for metabolic markers. The 40:1 myo-inositol:D-chiro-inositol blend reflects the ratio found in normal human blood plasma and is marketed as physiologically optimal for PCOS, but this specific ratio is covered by pharmaceutical patents held by Lo.Li. Pharma S.r.l., and a substantial share of the supporting research was authored by researchers affiliated with the patent holder — a conflict of interest worth factoring into how strongly to weight "40:1 is best" marketing claims (EP2782559B1; PMC7140126).
Is myo-inositol safe to take with metformin or other diabetes medication?
Myo-inositol generally causes fewer GI side effects than metformin (Teede 2023), but because both act as insulin sensitizers, combined use with metformin, insulin, or sulfonylureas could theoretically produce additive glucose-lowering effects and should be monitored by a clinician rather than self-combined (Open Heart).
How much myo-inositol should I take?
Most PCOS metabolic-marker trials used 2–4 g/day, and tolerability data show doses up to 18 g/day for 3 months or 4 g/day for 12 months were well tolerated (Open Heart). However, the 2023 guideline explicitly states that specific doses or combinations "cannot currently be recommended... due to a lack of quality evidence," so any specific dosing decision should be made with a clinician rather than based on a single product's marketing (Teede 2023).
Is myo-inositol regulated or approved as a drug?
In the US, inositol is Generally Recognized As Safe (GRAS) as a food additive and dietary supplement, not an approved drug for PCOS or infertility (CIR report). This means product quality, dose accuracy, and purity are not subject to the same premarket review as pharmaceuticals, consistent with the guideline's caution that "regulatory status and quality control of inositol in any form... can differ from those for pharmacological products and doses and qualities may vary" (Teede 2023).
Sources and funding notes
- Fitz 2024, "Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines," J Clin Endocrinol Metab — independent, publicly-funded academic consortium.
- Teede 2023, "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome," J Clin Endocrinol Metab — independent international guideline panel.
- Flinders University, full-text PDF of the 2023 PCOS guideline recommendations.
- DiNicolantonio & O'Keefe 2022, "Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome," Open Heart — independent cardiology narrative review/editorial.
- PMC6617769, review of inositol safety/efficacy for insulin resistance.
- PMC10692440, meta-analysis of myo-inositol for gestational diabetes prevention (6 RCTs, n=887).
- Unfer 2017, "Myo-inositol effects in women with PCOS: a meta-analysis," Endocrine Connections — flagged, lead author holds MYO:DCI ratio patents.
- Pundir 2022, "Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis," PubMed — independent, found largely null results.
- PMC8371888, network meta-analysis comparing metformin, thiazolidinediones, inositol, and berberine in PCOS.
- Nordio 2019, "The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation," PubMed — flagged, overlapping authorship with patent-affiliated researchers.
- PMC7140126, "Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary," International Journal of Endocrinology — discusses 40:1 ratio origins and history including the Insmed Pharmaceuticals DCI patent.
- Clinical Medicine Insights: Case Reports, PMC10981332, case series on a patented 3.6:1 MYO:DCI ratio.
- EP2782559B1, "Pharmaceutical composition comprising myo-inositol and D-chiro-inositol," Lo.Li. Pharma S.r.l. / inventor Vittorio Unfer — industry patent, disclosed financial interest.
- Taylor & Francis, "Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome" — reviews ratio evidence and its limitations.
- Reproductive BioMedicine Online, 2025 commentary on myo-inositol in PCOS fertility management.
- Laganà 2024, expert opinion on inositols in PCOS and type 2 diabetes.
- PMC10886614, comparative effects of myo-inositol and metformin therapy.
- Open Heart, review of myo-inositol mechanisms and PCOS trial history.
- Cosmetic Ingredient Review (CIR) report on inositol, referencing US GRAS status.
- NutraIngredients/Spate, coverage of inositol as a rising women's-health supplement trend.
Last reviewed: July 4, 2026.